Camurus AB (publ)
Ideon Science Park
Lund 223 70
Sweden
46 4 62 86 57 30
https://www.camurus.com
版塊: Healthcare
行業: Biotechnology
全職員工: 218
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Fredrik Tiberg | President, CEO, CSO & Director | 12.06M | 無 | 1963 |
| Mr. Jon U. Garay Alonso | Chief Financial Officer | 無 | 無 | 1973 |
| Mr. Torsten Malmstrom | Chief Technology Officer | 無 | 無 | 1968 |
| Mr. Rein Piir B.Sc. | Vice President of Investor Relations | 無 | 無 | 1958 |
| Ms. Maria Lundqvist | Global Head of Human Resources | 無 | 無 | 1966 |
| Mr. Markus Johnsson | Senior Vice President of R&D | 無 | 無 | 1972 |
| Mr. Fredrik Joabsson | Chief Business Development Officer | 無 | 無 | 1972 |
| Mr. Richard Jameson | Chief Commercial Officer | 無 | 無 | 1964 |
| Mr. Alberto M. Pedroncelli | Chief Medical Officer | 無 | 無 | 1964 |
描述
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as licensing agreement with Solasia Pharma. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden. The company operates as a subsidiary of Sandberg Development AB.
公司管治
截至 2024年6月1日 止，Camurus AB (publ) 的 ISS 管治質素評分為 4。 Pillar 分數正在審核中：8；董事會：6；股東權利：1；現金賠償：4。
